|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Company Outlook to 2011: Financial and Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Datamonitor, Dec 2006, Pages: 192
Based on an analysis of 46 companies and 1,000+ products, we forecast that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
Scope of this title:
- Financial and Strategic Analysis of the Sales Outlook to 2011 for Big Pharma, Mid Pharma, Japan Pharma and Biotech
- Quantitative analysis of the revenue balance of launches and expiries for each peer set member to 2011
- Assessment of current and forecast 2011 therapeutic focus and product type focus for each peer set member
2002-2006 operating cost and EBIT margin analysis for each peer set member
Highlights of this title:
- Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of pharma space to increase presence in medical devices, diagnostics and consumer healthcare.
- Biotech will be the fastest growing peer set with a 10.1% sales CAGR 2005-11. Biotech is almost totally insulated from generic threat because (1) biotech portfolios are often too young to contain expired products and (2) even if products have expired, the predominantly biologic nature of biotech portfolios is a major barrier to generic entry.
- The fastest growing Japanese companies (such as Daiichi-Sankyo and Astellas) will receive the majority of their growth from expanding sales of already marketed products whereas the slowest growing companies (such as Takeda and Eisai) are burdened with heavy sales declines from patent expiries particularly in the gastrointestinal therapy area.
Reasons to order your copy:
- Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody companies
- Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set
- Learn how biotech faces slowing growth momentum due to second generation biologics cannibalizing sales of first generation predecessor products.
Customers who bought this item also bought
The Pharmaceutical Company Outlook to 2012: Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Big Pharma Turns to Biologics for Growth to 2010: Financial and Strategic Segmentation of the Big Pharma Sector by Drug Technology
Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape
The Rise of Mid-Sized Pharma
Bio/Pharma R&D Statistical Sourcebook 2008/2009
Nycomed A/S (Incl. Altana Pharma Ag): Pharmavitae Profile
Premium Company Profile - Antares Pharma
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
Mid Pharma Sector: In-licensing and Other Externalization Strategies
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Drug Delivery Partnering Agreements in Pharma and Biotech
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
|
|
|
|
